Allergan PLC Chairman and CEO Brent Saunders dismissed any speculation that the company might give in to investor advocacy for splitting up those two leadership roles during the company’s second quarter earnings call July 26. He cited ongoing R&D success as stabilizing the firm’s future commercial prospects, and noted it is taking a cautious approach to divesting its women’s health and infectious disease units.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?